1
|
Piraux A, Angibaud M, Nizet P, Navas D, Sallenave-Namont C, Prot-Labarthe S, Huon JF. Factors influencing French community pharmacists' willingness to participate in research projects: a mixed method study. BMC PRIMARY CARE 2023; 24:229. [PMID: 37919662 PMCID: PMC10623853 DOI: 10.1186/s12875-023-02163-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 09/27/2023] [Indexed: 11/04/2023]
Abstract
BACKGROUND French community pharmacists are facing an increasing demand to provide a wider range of services to meet the needs of the population. These new missions must be evaluated by primary care research studies. This study aims to explore the factors that influence French community pharmacists' willingness to participate in research projects. METHODS A mixed-method design was adopted for this study, comprising an initial quantitative online survey followed by semi-directed interviews. The investigation was conducted at two French faculties of pharmacy, Angers and Nantes, involving students in their 6th and final year of pharmacy education, and their community pharmacist tutors. The survey items were based on a study by Saini et al. and participants responded using five-point Likert scales. The semi-directed interviews were conducted after the quantitative analysis, only with volunteer and already graduated community pharmacists. RESULTS A total of 131 people participated in the quantitative analysis, comprising 75 students and 56 pharmacists. Pharmacists and students agreed on the significance of two key aspects: the research must possess a clear and meaningful purpose, and researchers must keep the pharmacists informed about the study's results. Among the 27 proposed items, only three showed significantly different results between students and pharmacists. Moreover, 11 semi-structured interviews were conducted. Research in the community pharmacy domain is relatively new for many pharmacists. Despite limited training, their willingness to participate is contingent on being actively involved from the outset, receiving appropriate support and training. However, the research should be seamlessly integrated into their daily practice, without being too time-consuming and administratively burdensome. Time constraints emerged as the main obstacle, along with concerns about the availability of human resources. Pharmacists expressed strong motivation driven by the research topic's relevance, and its potential impact on patients or the profession. While financial compensation is desirable, it did not appear to be the main criterion for participation in a study. CONCLUSIONS French pharmacists are willing to participate in research projects to improve patient care and develop the profession. Research teams must guide and involve from the project's inception.
Collapse
Affiliation(s)
- Arthur Piraux
- Department of Pharmacy, Univ Angers, CHU Angers, Angers, F-49000, France.
| | - Morgane Angibaud
- Primary Care Federative Department, Faculty of Medicine, University of Nantes, Nantes, F-44000, France
| | - Pierre Nizet
- UMR INSERM 1246 SPHERE "methodS in Patient-centered Outcomes and HEalth ResEarch, Nantes Université, Université de Tours, Nantes, France
- Nantes Université, CHU Nantes, Pharmacie, Nantes, F-44000, France
| | - Dominique Navas
- Nantes Université, CHU Nantes, Pharmacie, Nantes, F-44000, France
| | - Claire Sallenave-Namont
- UR2160 ISOMer - UFR de Sciences Pharmaceutiques et biologiques, Université de Nantes, Nantes, F- 44035, France
| | - Sonia Prot-Labarthe
- Nantes Université, CHU Nantes, Université Paris Cité, Inserm, ECEVE, F- 75010, Pharmacie, Paris, France
| | - Jean-François Huon
- UMR INSERM 1246 SPHERE "methodS in Patient-centered Outcomes and HEalth ResEarch, Nantes Université, Université de Tours, Nantes, France
| |
Collapse
|
2
|
Ababneh BF, Ong SC, Mahmoud F, Alsaloumi L, Hussain R. Attitudes, awareness, and perceptions of general public and pharmacists toward the extended community pharmacy services and drive-thru pharmacy services: a systematic review. J Pharm Policy Pract 2023; 16:37. [PMID: 36864499 PMCID: PMC9979876 DOI: 10.1186/s40545-023-00525-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 01/18/2023] [Indexed: 03/04/2023] Open
Abstract
BACKGROUND Several extended and newly added pharmacy services were evaluated in different countries. This review aims to provide a summary of studies on attitudes, awareness, or perceptions toward various extended and drive-thru pharmacy services at community settings among pharmacists and the general public. METHODS To find qualitative and descriptive quantitative studies, that reported on the attitudes, awareness, or perceptions of the general public and pharmacists toward the practice of any extended community pharmacy service and drive-thru pharmacy services in a community setting and conducted from March 2012 to March 2022. Researchers used databases such as Embase, Medline PubMed, Scopus, Web of Science, and Science Direct. The reviewers extracted data independently using the PRISMA checklist. RESULTS There were 55 studies found according to the inclusion criteria. Various extended pharmacy services (EPS) and drive-thru pharmacy services were noted in the community setting. Pharmaceutical care services and healthcare promotion services were the noticeable performed extended services. There were positive perceptions and attitudes toward extended and drive-thru pharmacy services among pharmacists and the public. However, some factors, such as lack of time and shortage of staff, affect the practice of those services. CONCLUSION Understanding the major concerns toward the provision of extended and drive-thru community pharmacy services and improving pharmacists' skills through more training programs to provide such services efficiently. In the future, more reviews for EPS practice barriers are recommended to faceup all concerns and find standardized guidelines by stakeholders and organizations for efficient EPS practices.
Collapse
Affiliation(s)
- Bayan F. Ababneh
- grid.11875.3a0000 0001 2294 3534Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
| | - Siew Chin Ong
- Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
| | - Fatema Mahmoud
- grid.11984.350000000121138138Discipline of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland UK
| | - Louai Alsaloumi
- grid.412132.70000 0004 0596 0713Discipline of Clinical Pharmacy, Faculty of Pharmacy, Near East University, Nicosia, Northern Cyprus Turkey
| | - Rabia Hussain
- grid.11875.3a0000 0001 2294 3534Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
| |
Collapse
|
3
|
Pharmacist-Managed Therapeutic Drug Monitoring Programs within Australian Hospital and Health Services—A National Survey of Current Practice. PHARMACY 2022; 10:pharmacy10050135. [PMID: 36287457 PMCID: PMC9607166 DOI: 10.3390/pharmacy10050135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/13/2022] [Accepted: 10/14/2022] [Indexed: 12/04/2022] Open
Abstract
Pharmacist-managed therapeutic drug monitoring (TDM) services have demonstrated positive outcomes in the literature, including reduced duration of therapy and decreased incidence of the adverse effects of drug therapy. Although the evidence has demonstrated the benefits of these TDM services, this has predominately been within international healthcare systems. The extent to which pharmacist-managed TDM services exist within Australia, and the roles and responsibilities of the pharmacists involved compared to their counterparts in other countries, remains largely unknown. A cross-sectional online survey was conducted evaluating pharmacist-managed TDM programs within Australian hospital and healthcare settings. Pharmacist perceptions were also explored about the strengths, weaknesses, opportunities, and barriers associated with implementing a pharmacist-managed TDM service. A total of 92 surveys were returned, which represents a response rate of 38%. Pharmacist-managed TDM programs were present in 15% of respondents. It is only in the minority of hospitals where there is a pharmacist-managed service, with pharmacists involved in recommending pathology and medication doses. The programs highlighted improved patient outcomes but had difficulty maintaining the educational packages and training. For hospitals without a service, a lack of funding and time were highlighted as barriers. Based on the findings of this survey, there is minimal evidence of pharmacist-managed TDM models within Australian hospital and health services. A standardized national approach to pharmacist-managed TDM services and recognition of this specialist area for pharmacists could be a potential solution to this.
Collapse
|
4
|
Elbeddini A, Tayefehchamani Y, Yilmaz Z, Villegas JJ, Zhang EY. Evaluation of a community-based memory clinic in collaboration with local hospitals to support patients with memory decline. J Taibah Univ Med Sci 2022; 17:220-234. [PMID: 35592795 PMCID: PMC9073869 DOI: 10.1016/j.jtumed.2021.05.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 05/06/2021] [Accepted: 05/09/2021] [Indexed: 11/15/2022] Open
Abstract
Objective This study evaluates the role of a specialised and multidisciplinary healthcare team, including a pharmacist, in providing medication management for patients with mild cognitive impairment (MCI) and dementia, in a memory clinic. Methods The study analysed the dataset of 102 patients of a geriatric and memory clinic in a rural area of Ontario, Canada. The case histories of the patients were reviewed a week before the clinic day and a pharmacist performed medication reconciliations. During the clinic day, cognitive tests were conducted and outcomes were discussed with the team, to create a care plan and schedule a follow-up within 3, 6 or 12 months. Results Most patients had an average of 5 prescriptions and 2 non-prescription medications deprescribed, and 57% of patients were started on memory-related medications. A total of 712 medications (p-value 0.001) were deprescribed, with 510 prescriptions and 202 non-prescription items. Out of the 712 deprescribed drugs, 374 were discontinued with no therapeutic substitutions, 202 were reduced in dosage and 136 were switched to a safer alternative. A total of 43 patients showed improved Activities of Daily Living (ADL) performance after 3 and 6 months and 68 patients showed improvement after 12 months. Conclusion This study highlights the importance of a multidisciplinary approach in addressing drug-therapy problems, medication optimisation, and deprescription in patients with dementia. The presence of a pharmacist in the multidisciplinary team enables impactful medication optimisation and leads to improved patient outcomes. This demonstrates the value of specialised expertise in medication management for patients with dementia.
Collapse
Affiliation(s)
- Ali Elbeddini
- Winchester District Memorial Hospital, Winchester, ON, Canada
| | | | - Zekiye Yilmaz
- Clinical Pharmacy Department, Acibadem University, Turkey
| | - Josiah J. Villegas
- University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada
| | | |
Collapse
|
5
|
Alefishat E, Jarab AS, Muflih S, Aqeel AW. Community pharmacists’ attitudes toward practice-based research and their perceived utilization of scientific evidence. PLoS One 2022; 17:e0264193. [PMID: 35290392 PMCID: PMC8923436 DOI: 10.1371/journal.pone.0264193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 02/06/2022] [Indexed: 12/03/2022] Open
Abstract
Background Enhancing the contribution of practicing pharmacists into scientific evidence via practice-based research (PBR) is crucial in maintaining high-quality clinical practice and healthcare delivery. Involving community pharmacists in PBR can potentially can also help break barriers to the utilization of the current best evidence in everyday pharmacy practice. The impact of pharmacists’ attitude towards PBR on their utilization of current best evidence in pharmacy practice is understudied. Objectives The aim of the study was to investigate the impact of community pharmacists’ attitudes toward PBR on their utilization of current best evidence, barriers for conducting PBR in clinical practice were also investigated. Methods In this cross-sectional study, 169 community pharmacists working across Jordan filled a questionnaire to assess their attitudes towards PBR, barriers to PBR, and their utilization of the current best evidence in clinical practice. Results Pharmacists in this study showed a positive attitude toward PBR (attitude mean score >3.5). A positive attitude towards PBR was associated with high utilization of the best current scientific evidence. We also investigated several barriers to PBR and their association with utilization those included; the lack of perceived benefits, lack of institutional support, and lack of self-engagements of community pharmacists to PBR. The lack of perceived benefit was found to be negatively associated with pharmacists’ utilization of the current best scientific evidence. Conclusion In this study, pharmacists’ utilization of current best evidence was found to be significantly impacted by their attitude toward PBR. The current study findings highlight the importance of supporting, promoting, and facilitating PBR among community pharmacists which can potentially enhance their utilization of the current best evidence in their everyday pharmacy practice.
Collapse
Affiliation(s)
- Eman Alefishat
- Department of Pharmacology, College of Medicine and Health Science, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- Department Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
- * E-mail:
| | - Anan S. Jarab
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
| | - Suhaib Muflih
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
| | - Abdel Wahab Aqeel
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
| |
Collapse
|
6
|
Obaid D, El-Dahiyat F, Babar ZUD. Recommendations to improve pharmacy practice research in the Middle Eastern Arab countries. J Pharm Policy Pract 2021; 14:68. [PMID: 34416916 PMCID: PMC8377453 DOI: 10.1186/s40545-021-00357-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 06/30/2021] [Indexed: 11/18/2022] Open
Abstract
The expansion of the pharmacist-led services has resulted in increased demand to have evidence in terms of necessity, efficacy, and cost. Evidence-based practice is crucial to provide the best patient health outcomes and pharmacy practice research can play a key role in this regard. This commentary provides a background of pharmacy practice research, and then, it highlights three key recommendations based on a systematic review of the literature. The systematic review of the literature on pharmacy practice research has been conducted in 12 Middle Eastern Arab Countries. The three key recommendations include (a) identification of research priorities by health authorities in each country; (b) pharmacy practice research culture to be nurtured and promoted with academic researchers and practitioners; and (c) shifting pharmacy practice research towards applied, interventional, and implementation studies
Collapse
Affiliation(s)
- Daneh Obaid
- College of Pharmacy, Al Ain University, P.O Box 64141, Al Ain, UAE
| | - Faris El-Dahiyat
- College of Pharmacy, Al Ain University, P.O Box 64141, Al Ain, UAE.
| | - Zaheer-Ud-Din Babar
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, West Yorkshire, UK
| |
Collapse
|
7
|
Almansour HA, Aloudah NM, Alhawassi TM, Chaar B, Krass I, Saini B. Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think? J Pharm Policy Pract 2021; 14:42. [PMID: 33958004 PMCID: PMC8100751 DOI: 10.1186/s40545-021-00319-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 04/21/2021] [Indexed: 11/10/2022] Open
Abstract
Background Cardiovascular disease (CVD) is an emerging contributor to national morbidity and mortality in Saudi Arabia. CVD risk prevention services are limited, particularly with an over-utilised public health sector and an under-utilised and under-resourced primary care sector. Globally, there is evidence that community pharmacists can play a key role in CVD prevention within primary care. However, the perspectives of policymakers and opinion leaders are critical to successful translation of evidence into practice. Thus, the aim was to engage policymakers and professional leaders in discussions about implementing high-quality CVD risk prevention services in community pharmacy. Methods Qualitative semi-structured interviews were conducted, audio-recorded and transcribed verbatim. All transcripts were thematically analysed. Results A total of 23 participants (87% male) from government and non-government sectors were interviewed. Of these, almost 65% had pharmacy qualifications. Limited provision of CVD risks preventative services in primary care was acknowledged by most participants and building community pharmacists’ capacity to assist in preventive health services was viewed favourably as one way of improving the status quo. The data yielded four key themes: (1) future pharmacy CVD health service models; (2) demonstrable outcomes; (3) professional engagement and advocacy; and (4) implementability. CVD health services roles (health screening, primary and secondary prevention services), pragmatic factors and tiered models of care (minimal, medium, and comprehensive pharmacist involvement) were discussed. The need for humanistic, clinical, and cost effectiveness outcomes to be demonstrated and active involvement of professional bodies were deemed important for such services to be sustainable. Professional pharmacy governance to develop pharmacy careers and workforce, pharmacy curricular reform and ongoing education were posed as key success factors for novel pharmacy roles. Practice policies, standards, and guidelines were seen as required to adhere to stringent quality control for future pharmacy services provision. Participant’s implementation vision for such services included scalability, affordability, access, adoption and health system reform. Most discussions focused on the need for structural improvement with limited input regarding processes or outcomes required to establish such models. Conclusions Most participants favoured pharmacy-based CVD risk prevention services, despite the variability in proposed service models. However, prior to developing such services, support structures at the health system and health professional level are needed as well as building public support and acceptability for pharmacy services. Supplementary Information The online version contains supplementary material available at 10.1186/s40545-021-00319-6.
Collapse
Affiliation(s)
- Hadi A Almansour
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Building Number A15, Sydney, NSW, 2006, Australia.
| | - Nouf M Aloudah
- College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Tariq M Alhawassi
- College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.,Medication Safety Research Chair, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Betty Chaar
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Building Number A15, Sydney, NSW, 2006, Australia
| | - Ines Krass
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Building Number A15, Sydney, NSW, 2006, Australia
| | - Bandana Saini
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Building Number A15, Sydney, NSW, 2006, Australia.,Woolcock Institute of Medical Research, Sydney, NSW, Australia
| |
Collapse
|
8
|
Woods P. Process philosophy: Organizing mentalities for glimpsing pharmacy practice 'in flight'. Res Social Adm Pharm 2021; 17:2082-2088. [PMID: 33895086 DOI: 10.1016/j.sapharm.2021.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 11/25/2022]
Abstract
There are increasing calls for the development of innovative research methods in pharmacy practice.1,2 This commentary seeks to illuminate pathways for 'thinking differently' about research approaches for pharmacy practice and social pharmacy by leaning on theoretical advances made in Organization and Management Science (OMS). In particular, the perspective of 'practical rationality',3 derived from a process philosophical world-view, is highlighted as a truly alternative framework for designing and enacting productive social research. To deliver practically rational findings, it is suggested "prior organization of mentalities and modes of thought"4 is required. Process philosophy, which has pre-Socratic beginnings,5 provides a comprehensive and unified perspective of reality, its character, and how we might understand ourselves in that reality. Process philosophy permits scope for exploring a variety of phenomena of the lived experience.6 Congruent methodologies can enable development of research processes and outcomes that capture a logic of pharmacy practice that more closely reflects practitioners' experience of that practice, thus narrowing the gap between theory and practice. Outcomes can provide a different and more complex 'system of picturing' phenomena and objects of study than more normative rationalistic, reductionist, quantitative approaches.7 Findings can reveal how patterned unfolding processes and practices interrelate and come together to produce some aspect of human life or work, providing new opportunities for intervention. The perspective also invites the re-focusing of qualitative approaches that eschew reductionism, toward concepts and processes that precede and indeed constitute the individualized person/agent/organization.8 The process philosophical perspective does not seek to compete with other paradigmatic approaches. Rather, it can deliver a radically different and complementary perspective, giving rise to new streams of inquiry that potentially deliver novel and insightful explanatory forms.4,9 It provides the opportunity for pharmacy practice research that may be able "to catch reality in flight".10.
Collapse
Affiliation(s)
- Phillip Woods
- School of Pharmacy and Medical Sciences, Parklands Drive, Southport Gold Coast campus, Griffith University, QLD 4222, Australia.
| |
Collapse
|
9
|
Babar ZUD. Ten recommendations to improve pharmacy practice in low and middle-income countries (LMICs). J Pharm Policy Pract 2021; 14:6. [PMID: 33407945 PMCID: PMC7788796 DOI: 10.1186/s40545-020-00288-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Medicines are important health interventions and their appropriate use could improve health outcomes. Throughout the globe, pharmacists play a very important role to improve the use of medicines. Though high-income countries are debating on futuristic approaches, independent prescribing of pharmacists, clinical skills, and to expand pharmacy services; a large majority of low and middle-income countries still lag behind to strengthen pharmacy practice. This paper presents a key set of recommendations that can improve pharmacy practice in low and middle-income countries (LMICs). The ten recommendations include (1) Mandatory presence of graduate-level pharmacists at community pharmacies (2) Clear demarcation of the roles and responsibilities of different categories of pharmacists (3) Effective categorization and implementation of medicines into (a) prescription medicines (b) pharmacists only medicines (c) over the counter medicines (4) Enforcement of laws and regulations for the sale of medicines (5) Prohibiting doctors from dispensing medicines (the dispensing separation between pharmacists and doctors). (6) Involving pharmacies and pharmacists in Universal Health Coverage Schemes to improve the affordability of medicines (7) Strengthening national medicines regulatory authorities to improve the quality, safety, and effectiveness of medicines (8) Training of pharmacists in clinical skills, vaccination, and minor ailment schemes (9) Promoting independent medicines information for consumers and healthcare professionals by developing national medicines information strategy (10) Mandatory Continuing Professional Development (CPD) programs for the Pharmacists.
Collapse
Affiliation(s)
- Zaheer-Ud-Din Babar
- Department of Pharmacy, Centre for Pharmaceutical Policy and Practice Research, University of Huddersfield, Queensgate, HD1 3DH, Huddersfield, UK.
| |
Collapse
|
10
|
Greenwood D, Steinke D, Martin S, Tully MP. Meeting patient expectations: Development of an Emergency Department Pharmacist Practitioner service specification. Res Social Adm Pharm 2020; 17:S1551-7411(19)30564-9. [PMID: 34756404 DOI: 10.1016/j.sapharm.2020.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 08/18/2020] [Accepted: 08/23/2020] [Indexed: 11/24/2022]
Abstract
BACKGROUND Emergency Department Pharmacist Practitioners (EDPPs) undertake both 'traditional' clinical pharmacy work, e.g. check prescriptions, and 'practitioner' work, e.g. perform clinical examinations. A recent study found a large variation in the extent and type of care provided. Whilst variation allows services to be tailored to local needs, it is important that care meets the minimum standards that are safe, effective, patient-centred, timely, efficient, and equitable. OBJECTIVE(S) To develop an EDPP service specification based on views of professional and patient stakeholders, primarily to support providers with delivery of high quality services. METHODS Patients, ED pharmacists and other ED healthcare professionals developed standards guided by the Institute of Medicine's quality domains. A panel of six ED pharmacists suggested and agreed on themes that should be included in the service specification. Additional themes were identified through interviews with eight patients who had been cared for by EDPPs as to their expectations of the service. Finally, a multidisciplinary expert panel of healthcare professionals and researchers reviewed and refined the service specification. RESULTS ED pharmacists developed 36 themes with consensus achieved for 25. Additional themes from the patient interviews concerned the communication and behaviour of EDPPs rather than specific clinical activities undertaken. Whilst patients were happy to be cared for by an EDPP working within their competence, for certain conditions (e.g. major trauma) they wanted a doctor as their main care provider. An evidence-based EDPP service specification of 52 criteria grouped into 4 categories was produced: direct patient care (29); other activities (10); general approach (10); and service structures (3). CONCLUSIONS As the product of both patient and expert input, EDs could align existing or newly developed services to the specification. Whether or not the specification actually improves the quality of EDPP services requires investigation, as does the absolute quality impact of services.
Collapse
Affiliation(s)
- Daniel Greenwood
- Division of Pharmacy and Optometry, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
| | - Douglas Steinke
- Division of Pharmacy and Optometry, University of Manchester, Oxford Road, Manchester, M13 9PT, UK
| | - Sandra Martin
- Division of Pharmacy and Optometry, University of Manchester, Oxford Road, Manchester, M13 9PT, UK
| | - Mary P Tully
- Division of Pharmacy and Optometry, University of Manchester, Oxford Road, Manchester, M13 9PT, UK
| |
Collapse
|
11
|
Cochran G, Bruneau J, Cox N, Gordon AJ. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Subst Abus 2020; 41:269-274. [PMID: 32697171 DOI: 10.1080/08897077.2020.1787300] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk. MOUD treatment rates continue to be low across the US, and currently, some evidence suggests access to evidence-based treatment is becoming increasingly difficult for those with OUD as a result of the 2019 novel corona virus (COVID-19). A major underutilized source to address these serious challenges in the US is community pharmacy given the specialized training of pharmacists, high levels of consumer trust, and general availability for accessing these service settings. Canadian, Australian, and European pharmacists have made important contributions to the treatment and care of those with OUD over the past decades. Unfortunately, US pharmacists are not permitted to prescribe MOUD and are only currently allowed to dispense methadone for the treatment of pain, not OUD. US policymakers, regulators, and practitioners must work to facilitate this advancement of community pharmacy-based through research, education, practice, and industry. Advancing community pharmacy-based MOUD for leading clinical management of OUD and dispensation of treatment medications will afford the US a critical innovation for addressing the opioid epidemic, fallout from COVID-19, and getting individuals the care they need.
Collapse
Affiliation(s)
- Gerald Cochran
- Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA
| | - Julie Bruneau
- Department of family medicine and emergency medicine, Université de Montréal, Montréal, Canada
| | - Nicholas Cox
- Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA
| | - Adam J Gordon
- Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.,Vulnerable Veteran Innovative PACT (VIP) Initiative; Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS Center), VA Salt Lake City Health Care System, Salt Lake City, Utah, USA
| |
Collapse
|
12
|
Hussain R, Dawoud DM, Babar ZUD. Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic. Res Social Adm Pharm 2020; 17:1920-1924. [PMID: 32792322 PMCID: PMC7373674 DOI: 10.1016/j.sapharm.2020.07.015] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/11/2020] [Accepted: 07/13/2020] [Indexed: 12/12/2022]
Abstract
Countries around the globe have responded to pandemic preparedness and developed strategies to cope with the COVID-19 crisis. In this context, the role of healthcare professionals is of paramount importance. Pharmacists are playing a vital role in dealing, preparedness, prevention, protection, promoting access to medicines and to improve health outcomes during this crisis. In this context, “Drive-thru” pharmacy services improve access to medicines while ensuring the preventive measures suggested by the World Health Organization. This commentary provides an overview of opportunities and challenges related to the implementation of “drive-thru pharmacy services” and their role in improving public health during this crisis.
Collapse
Affiliation(s)
- Rabia Hussain
- Department of Social and Administrative Pharmacy, Universiti Sains Malaysia, 11800, Pulau Penang, Malaysia.
| | - Dalia M Dawoud
- Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
| | - Zaheer-Ud-Din Babar
- Department of Pharmacy, University of Huddersfield, Queensgate, HD1 3DH, Huddersfield, United Kingdom
| |
Collapse
|
13
|
"If I were to do this, how would I experience it?" Developing a theoretical framework for exploring pharmacists' practice in the domain of assisted dying. Res Social Adm Pharm 2020; 17:685-693. [PMID: 32616431 DOI: 10.1016/j.sapharm.2020.05.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 05/07/2020] [Accepted: 05/25/2020] [Indexed: 11/21/2022]
Abstract
BACKGROUND Worldwide, pharmacy practice is changing to include new roles and responsibilities. Laws enabling the implementation of assisted dying are expanding in international jurisdictions. Pharmacy practice in assisted dying is subsequently expanding. However, studies of how pharmacists experience their practice when engaged in assisted dying are absent. To progress research into the lived experiences of pharmacists practicing in assisted dying, the development of an inquiry framework to guide such research is the first step. OBJECTIVE The objective was to develop a theoretical framework of inquiry for use in subsequent continuing research which may explore the actual experience of pharmacy practice in assisted dying. METHODS Perspectives were gathered from expert and senior pharmacists who were anticipating the imminent implementation of assisted dying practice. Analysis focused on understanding what aspects of practice experience were important to them. Interview-conversations centred on the question: If you had the chance to talk to experienced pharmacist practitioners who have been involved in the practice of assisted dying, what aspects regarding their experiences, would you like to know about? A conventional approach to qualitative content analysis was utilized to analyze the data. RESULTS Findings summarized questions posed by pharmacists contemplating the implementation of assisted dying practice. These perspectives formed the foundation of a theoretical inquiry framework constituted by 8 inter-related dimensional range-continuums. Each range-continuum, designed to explore the lived experiences of pharmacists in practice, is defined. Examples of how the inquiry dimensions will be used to inform future exploratory research are offered within the framework. CONCLUSIONS The theoretical inquiry framework will be used to develop knowledge for pharmacists contemplating participation (or not) in assisted dying practice. It is timely to progress research that reveals the informed experiences of pharmacists that are actually practicing in this area. The framework may be adapted for researching pharmacists' experience in other practice areas and contexts.
Collapse
|
14
|
Karia AM, Balane C, Norman R, Robinson S, Lehnbom E, Durakovic I, Laba TL, Joshi R, Webster R. Community pharmacist workflow: Space for Pharmacy-based Interventions and Consultation TimE study protocol. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2020; 28:441-448. [PMID: 32347607 DOI: 10.1111/ijpp.12625] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 03/24/2020] [Accepted: 03/26/2020] [Indexed: 11/30/2022]
Abstract
BACKGROUND Pharmacists' roles are expanding to delivering a wider set of professional services including medication management optimisation, vaccinations and screening services. Robust research determining whether pharmacists have the capacity to offer such services in the Australian community pharmacy setting is lacking. This protocol details a mixed methods study that investigates the variation in pharmacists' daily tasks and the workspace they work in as a measure of their workload capacity for expanding pharmacy services. METHODS An observational time and motion study will be conducted in up to twenty community pharmacies in metropolitan and rural regions of Australia. A trained observer will follow a pharmacist and record the type, location and duration of tasks undertaken over the course of their working day. Data will be collected and analysed using the electronic Work Observation Method By Activity Timing (WOMBAT) tool. Pharmacists' work patterns will be described as time for each task, and by proportionating multitasking and interruptions. This information will be combined with workspace data collected using floor plans, photographs and a qualitative assessment of the working environment completed by the observer. Analysis will include heat-mapped floor plans visually highlighting pharmacist movements. DISCUSSION Pharmacists may provide solutions to the strained health workforce and system. There is limited quantitative evidence on whether pharmacists have the time or work setting to support such needs. The use of time and motion methodology is novel to Australian community pharmacy research, and the findings will provide a better understanding of pharmacists' capacity and work environment.
Collapse
Affiliation(s)
- Ajay Mahendrarai Karia
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
| | - Christine Balane
- The George Institute for Global Health, UNSW, Sydney, NSW, Australia
| | - Richard Norman
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
| | - Suzanne Robinson
- Health Systems Health Economics, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
| | - Elin Lehnbom
- Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway.,Department of Health and Caring Sciences, Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden
| | - Iva Durakovic
- Interior Architecture, Faculty of Built Environment UNSW, Sydney, NSW, Australia
| | - Tracey-Lea Laba
- Centre for Health Economics Research and Evaluation, The University of Technology Sydney, Sydney, NSW, Australia.,The George Institute for Global Health, UNSW, Sydney, NSW, Australia
| | - Rohina Joshi
- Faculty of Medicine, The George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.,The George Institute for Global Health India, New Delhi, India
| | - Ruth Webster
- Technical Transfer, The George Institute for Global Health, UNSW, Sydney, NSW, Australia
| |
Collapse
|
15
|
Woods P, Schindel TJ, King MA, Mey A. Pharmacy practice in the domain of assisted dying: A mapping review of the literature. Res Social Adm Pharm 2020; 16:267-276. [DOI: 10.1016/j.sapharm.2019.05.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 05/15/2019] [Accepted: 05/19/2019] [Indexed: 10/26/2022]
|
16
|
Ake A, Arcand M. The impact of mobile health monitoring on the evolution of patient-pharmacist relationships. INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING 2020. [DOI: 10.1108/ijphm-04-2019-0030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose
Increasingly popular mobile health technology is creating a new paradigm for the delivery of care to patients involving a role of the pharmacist. This study aims to propose a renewed patient–pharmacist relationship in this environment and present an empirical case study investigating the influence of key variables, including the consumer’s attitude toward personalized monitoring performed by the pharmacist, on the intention to adopt a mobile health app. Other drivers identified were ease of use and perceived usefulness of the app, individual and health-related factors (perceived vulnerability and severity of health condition, social norms and innovativeness with technology) and quality of relationship with the pharmacist.
Design/methodology/approach
A self-administered online survey was completed by 356 Canadian mobile device owners of more than 40 of age. Analyses were performed using structural equation modeling.
Findings
The main factor driving adoption intentions was perceived usefulness followed by the respondent’s innovativeness with technology and perceived vulnerability of his/her health condition. Attitude toward personalized monitoring depends primarily on the relationship with the pharmacist. No relationship was found between adoption intentions and attitude toward personalized monitoring.
Originality/value
This research features a multidisciplinary approach by using variables from relational marketing, information technology and health and inclusion of the pharmacist (vs physician) as a health consultant, offering relevant marketing avenues for pharmacists.
Collapse
|
17
|
Nagaria RA, Hasan SS, Babar ZUD. Pharmacy, pharmaceuticals and public policy: Solving the puzzle. Res Social Adm Pharm 2019; 16:840-843. [PMID: 31351779 DOI: 10.1016/j.sapharm.2019.07.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 07/16/2019] [Accepted: 07/18/2019] [Indexed: 10/26/2022]
Abstract
Increasing pressure on healthcare demand and delivery has resulted in the development of new roles and services for pharmacists. As current models of pharmacy practice continue to be evaluated, pharmacists must be involved in identifying new areas that may require research. In order to do so, the current vision of the future of pharmacy practice is discussed in this commentary. Issues such as adequate funding, professional competency and building strong interprofessional relationships are still identified as major barriers to change. These barriers have been grouped into the themes that form a conceptual model of the factors affecting the future of pharmacy practice, which have led to the development of key questions for the future.
Collapse
Affiliation(s)
- Raveena Amee Nagaria
- Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, United Kingdom.
| | - Syed Shahzad Hasan
- Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, United Kingdom
| | - Zaheer-Ud-Din Babar
- Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, United Kingdom
| |
Collapse
|